Alzheimer's disease (AD) is a neurodegenerative disease with an insidious onset and progressive course that inevitably leads to death. The current diagnostic tools do not allow for diagnosis until the disease has lead to irreversible brain damage. Genetic studies of autosomal dominant early onset familial AD has identified three causative genes: amyloid precursor protein (APP), presenilin 1 and 2 (PSEN1 and PSEN2). We performed a global gene expression analysis on fibroblasts from 33 individuals (both healthy and demented mutation carriers as well as wild-type siblings) from three families segregating the APP SWE, APPARC and PSEN1 H163Y mutations, respectively. The mutations cause hereditary progressive cognitive disorder, including typical autosomal dominant AD. Our data show that the mutation carriers share a common gene expression profile significantly different from that of their wildtype siblings. The results indicate that the disease process starts several decades before the onset of cognitive decline, suggesting that presymptomatic diagnosis of AD and other progressive cognitive disorders may be feasible in the near future.
A
lzheimer's disease (AD) is the most common form of dementia and leads to irreversible neurodegenerative damage of the brain. The disease progression of AD is slow, and it may take several years from onset of cognitive decline to diagnosis. The current diagnostic tools (1-3) have poor sensitivity, especially for the early stages of the disease and do not allow for diagnosis until the disease has lead to irreversible brain damage. Common problems in the early diagnosis include trying to decide whether a patient's cognitive problems are due to dementia or depression and whether a patient has AD or one of the rarer degenerative dementias presenting with similar clinical symptoms. Thus, identification of early and reliable diagnostic markers has become a major research effort in the past 10 years. Because the clinical and neuropathological manifestations of familial AD (FAD) and nonfamilial AD are indistinguishable, except for the age of onset and the family history (4) , further studies of the familial forms may provide an avenue for identifying early diagnostic markers of AD. Here, we have taken advantage of this fact and used samples from family members known to carry a disease-causing mutation but who have not yet developed symptoms. In the present study, we performed a global gene expression analysis on siblings from families segregating the Swedish and Arctic amyloid precursor protein (APP) mutations as well as the H163 Y presenilin 1 (PSEN1) mutation. APP SWE (KM670͞671NL) and PSEN1 H163Y are FAD mutations that elevate the extracellular concentrations of amyloid-␤ (5, 6) . Contrary to the original investigations (7) , present studies suggest an increase in extracellular levels of Arctic amyloid-␤ as well.
ʈ The APP ARC mutation (E693G) gives a clinical phenotype indistinguishable from AD, but a recent report of the neuropathology of one patient shows congophilic angiopathy and Congonegative but argentophilic ''ring''-like plaque formations.** This morphological feature differs from well known idiopathic and FAD forms.** Involvements of hippocampus and the precipitation in the cortex may explain the clinical picture of progressive dementia disorders.
Different approaches have been used to elucidate the molecular and cellular malfunctions that contribute to the disease pathogenesis in AD (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Among the tissues studied are neuronal tissue, skin fibroblasts, platelets, lymphocytes, and body fluids, such as plasma and cerebrospinal fluid (18) . The use of peripheral tissues can be motivated if the disease can be considered to be systemic with perturbations throughout the body. For example, cultured skin fibroblasts have been used successfully to elucidate the molecular and biochemical basis of inborn errors of metabolism that cause neurological disease, such as Refsum disease (19) and Lesch-Nyhan syndrome (20) . Another approach has been to identify biomarkers for early diagnosis, prognosis, and treatment. Expression profiling has recently proved fruitful in providing a tool for classification of disease subtypes with implications for prognosis and management, particularly in cancer (21) (22) (23) (24) (25) (26) . In the present study, we investigated whether constitutional mutations in APP and PSEN1, which inevitably lead to AD and dementia, lead to detectable changes in the gene expression profile in fibroblasts for possible use in early diagnosis.
Materials and Methods
FAD Families. Thirty-three individuals from three families with dominant mutations in APP and PSEN1 were enrolled in the study: the APP K670N͞M671L Swedish mutation, APP SWE (n ϭ 12), the APP E693G Arctic mutation, APP ARC (n ϭ 13) and the PSEN1 H163Y mutation (n ϭ 8) ( Table 1 ). The APP SWE and PSEN1 H163Y mutations lead to typical autosomal dominant early onset AD, whereas the APP ARC mutation leads to an indistinguishable clinical phenotype. However, a recent report describes that the neuropathology in a patient with the APP ARC mutation is distinct from that of AD by the presence of heavy congophilic angiopathy in leptomeningeal and cortical-parenchyma arteries. In addition, almost all neocortical regions are mainly abundant by noncored, Congo-negative but argentophilic ring-like plaque formations. In the hippocampal region, the neurofibrillary tangle is the predominant feature, whereas the cortex is almost absent of neurofibrillary tangle changes. Demented and nondemented mutation carriers from all three mutation families and healthy wild-type siblings were included in the study. One wild-type spouse was also included. The average age of onset in the APP SWE family, the APP ARC family, and the PSEN1 H163Y family was 54 (27) , 56 (unpublished data), and 47 (28) years of age, respectively. All subjects were clinically examined and diagnosed according to the National Institute of Neurological and Communicative Diseases and Stroke͞ Alzheimer's Disease and Related Disorders Association criteria. The genotypes were determined by DNA sequencing. Ethical permission was obtained from the local ethical committee at Karolinska Institutet and informed consent was obtained from all participants. To protect privacy we do not publish gender and age of individual samples.
Skin Fibroblast Culturing and RNA Preparation. A small biopsy was taken from each individual from the inside of the upper arm under local anesthesia. Cultivation of the cells begun at the Karolinska University Hospital, Huddinge on the same day as the biopsy was taken. When each sample had reached 4 ϫ 10 6 cells, the cells were frozen in aliquots (10 6 cells per cryotube) and stored in liquid nitrogen (29) . In this study, one cryotube (10 6 cells) from each individual was rapidly thawed in a 37°C water bath and cultured in T25 flasks in supplemented medium containing 100% MEM with Earle's salt, 10% FBS, 1.2% L-glutamine, and 1.2% PeSt (all reagents were obtained from Life Technologies, Grand Island, NY). After 3-4 days, when the cells were confluent, they were split into T25 flasks (25,000 cells per flask) or into T75 flasks (75,000 cells per flask). The fibroblasts were harvested at confluency after reaching stationary phase. There was no significant difference in the number of passages in the two genotype groups (mutation carriers versus wild type) [average number of passages, 6.9 (range 4-12) versus 6.9 (range 5-11) in 30 samples (excluding F2, F16, and F33)]. The cells were treated with trypsin-EDTA (Invitrogen), centrifuged 400 ϫ g for 5 min, and the pellets were washed twice in PBS. The pellets were then quickly frozen in ethanol-CO 2 ice and transferred to Ϫ70°C. Total RNA was isolated from the cultured fibroblast pellets (3 ϫ 10 6 to 10 7 cells) by using an RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol, which gave a yield of 5-10 g of RNA per 10 6 cells.
Microarray Experiment. For microarray probing, reverse transcription, second-strand synthesis, and probe generation were performed according to the GeneChip Expression Analysis Technical Manual (Affymetrix, Santa Clara, CA). The generated probe was subjected to hybridization to oligonucleotide DNA chips, Human Genome U133A (Affymetrix). The arrays were scanned with a GeneArray Scanner (Hewlett-Packard).
Image Analysis and Data Quality Control. Scanner output image files were normalized and filtered by using MICROARRAY SUITE 5.0 software (Affymetrix). Normalization was performed by global scaling, with the arrays scaled to an arbitrary signal intensity value of 100. The detection metric (Presence or Absence calls) and decision of significant gene expression for a particular gene (probe set) was determined by using default parameters in the MICROARRAY SUITE 5.0 software. Data from three samples (one demented APP ARC mutation carrier, one presymptomatic APP SWE mutation carrier, and one healthy nonmutation wild type) were excluded from further analysis because of low global signal intensity, i.e., the scaling factor differed by Ͼ2.0 SD from the overall obtained average. Furthermore, signals from 9,752 of the 22,238 probe sets on the DNA chip were called Absent in all 30 samples, and they were excluded from further analysis. The highest signal value of any of the probe sets thus omitted was 43.9 on average. Therefore, we removed another 1,348 probe sets whose highest signal value was Ͻ44. Thus, hybridization data from 30 samples of the remaining 11,138 probe sets were used in the following analysis.
Statistical Analysis. Selection of differentially expressed probe sets were performed by using Allen's cross validation (CV) criterion (details are available from the authors upon request). Hierarchical clustering and principal component (PC) analysis (PCA) (30) were preformed by DICISIONSITE 7.1 (Spotfire, Somerville, 
Fibroblast specimens were donated by 33 members of three families with the APP SWE, APPARC, and PSEN1 H163Y mutations, respectively. Samples were collected from wild-type and mutation carrier siblings in each family. One wild-type spouse ( †) was also included. Three samples ‫)ء(‬ did not pass the filtering procedure in MAS 5.0 and were therefore excluded from further analysis. For more details about the filtering procedure, see Materials and Methods. Classification of samples was based on genotype (1, mutation carrier; 2, wild type), phenotype (1, demented; 2, presymptomatic; -, healthy, wild-type siblings), gender, age, and APOE 4 status (1, 4 present; 2, 4 absent), respectively. The ratios of male to female mutation carriers and wild types was 13:8 and 6:6, respectively. Nine mutation carriers were 49 years of age or younger, and 12 were classified as older. Five wild-type siblings were classified as young (56 years of age or younger), and six were classified as older. The age groups (age at biopsy) were defined by the median value dividing older and younger individuals in the mutation carrier and wild-type classes, respectively. Classifications were carried out similarly for all 30 samples: 19 mutation carriers and 11 wild-type samples.
MA) after normalizing signal values to Z scores among samples. Hierarchical clustering (complete linkage clustering) was performed by using cosign correlation as a similarity measurement. R 1.5.1 and R package e1071 were used for support vector machine (SVM) (31) with linear kernel and Fisher's linear discriminant analysis (32) . Leave-one out CV (LOOCV) was used to evaluate the robustness of the ''genotype-dependent'' discrimination in the SVM analysis. For example, the genotypes of 29 of 30 samples were successfully predicted with a CV threshold value of 3, giving a classification accuracy of 97%. To study the probability of getting similar accuracies by chance on randomly assigned classes of the data, random permutation experiments were performed with the same SVM scheme. The permutation was done by randomly assigning class labels on the whole data set (while keeping the true proportion of the two classes, here the proportion of 19 mutation carrier and 11 wild-type samples). After calculation of CV values for each of the randomized 10,000 permutated data sets, a LOOCV test was performed by using genes with CV values Ͼ3. Only 133 of the 10,000 randomly generated data sets (1.33%) showed a success rate (class predictability) of Ͼ97%.
The specific topological location and the distance to the discrimination plane in the PCA are determined by the gene expression profile of the individual sample. The formula for the FAD index was provided by calculating the coordinates of the three PC axes for all 30 samples, separately, using the discriminant function obtained based on Fisher's linear discriminant analysis (32) . The level of similarity between a test sample and the mutation carriers (FAD index) was obtained by substituting X, Y, and Z, where positive values indicates similarity to mutation carriers in the formula below.
Here,
X, Y, and Z are the coordinates of the test sample on the three PC axes. P 1i , P 2i , and P 4i are eigenvector components of the first, second and fourth PC axes, respectively, i and i are the mean and SD of the 30 samples of the ith probe set, respectively, and i is the expression signal value of the ith probe set of the unknown test sample (further information is available from the authors upon request).
Results
To study the potential gene expression changes accompanying the early stages of AD, Affymetrix Human Genome U133A GeneChip arrays containing 22,238 probe sets were used to monitor the gene expression profiles of skin fibroblasts obtained from 33 members of three different families segregating the FAD mutations: APP SWE , APP ARC, or PSEN1 H163Y (Table 1) . Three samples and 11,100 probe sets were excluded by the filtering procedure using MICROARRAY SUITE 5.0, resulting in further hybridization data analysis of the remaining 11,138 probe sets from 30 samples [APP SWE (n ϭ 11), APP ARC (n ϭ 12), and PSEN1 H163Y (n ϭ 7)].
Identification of a Gene Expression Signature That Significantly Distinguishes Mutation Carriers from Wild-Type Siblings.
To find out whether the mutated genes induce a common expression change in the FAD fibroblasts compared with wild types, we classified the samples into mutation carriers (including the demented and presymptomatic siblings) and wild-type control siblings. No quantitative differences were found in the gene expression levels of APP or PSEN1 between the two classes (data not shown). Selection of differentially expressed probe sets (genes) were performed by using Allen's CV criterion (8) by which a CV value is generated for each gene on the array as described in Fig. 1 .
Positive CV values indicate that the signal intensity of the gene expression signal depends on the sample class, here, mutation carriers (regardless of type of mutation) versus wild type. Fig. 2 shows the number of genes with a significantly differential expression profile at different CV value thresholds. As shown in Fig. 2 , we identified 56 genes with a CV value of Ͼ4 and 200 genes with a CV value of Ͼ3. A list of the genes with a CV value of Ͼ3 is available from the authors upon request. Subsequently, we assessed whether the signal intensities of the identified genes could reliably predict each sample's genotype. This analysis was performed with a powerful supervised machine learning method, SVM (31), which is used to discriminate between two classes of samples. The signal intensities of 200 genes, corresponding to the genes with CV values of Ͼ3, were used as input to the SVM. This method successfully identified a hyperplane that perfectly separated the samples into two classes: one with 19 mutation carriers and the other with the remaining 11 wild-type controls (data not shown). To evaluate the robustness of the genotype-dependent discrimination in the SVM analysis, we performed a LOOCV, in which the hyperplane was defined from the gene expression data of 29 samples, followed by a validation of whether the remaining single sample could be classified correctly. We repeated the LOOCV for CV thresholds of 1, 2, 3, 4, and 5. As shown in Fig. 2 , the highest predictability The samples were divided into two categories, ''High'' or ''Low,'' depending on their signal intensity with respect to the midpoint of the signal intensity between the maximum value and the minimum value [(max ϩ min)͞2] of all samples. Samples that fall above the midpoint value were scored as High, and samples that fall below the midpoint value were scored as Low, i.e., upper and lower rows consist of samples with values higher and lower than the midpoint of the signal intensity, respectively. Left and right columns consist of samples that belong to class 1 (F) and class 2 (OE), respectively. Allen's CV criterion of the independent and the dependent models were calculated as log likelihoods.
of sample genotype was obtained by using CV threshold values of 3 and 4. For example, the genotypes of 29 of 30 samples were successfully predicted with a CV threshold value of 3, giving a classification accuracy of 97%. Random permutation experiments were used to determine the statistical significance of the obtained classification accuracy. Permutations indicate that the three FAD mutations have a significantly different expression profile in fibroblasts compared with their wild-type siblings in the control group (P ϭ 0.01).
A Unique Gene Expression Signature Among Three Different Types of FAD. Unsupervised two dimensional hierarchical clustering was performed for the selected 56 (CV Ͼ 4) and 200 (CV Ͼ 3) genes, respectively. As shown in Fig. 3 , clusters of differentially up-and down-regulated genes between the mutation carriers and their wild-type siblings were identified. Moreover, the dendrogram separated the mutation carriers into one cluster, which was separated from the cluster of wild-type siblings. In the case of the 56 probe sets, the mutation carriers could be separated from the wild-type samples already at the highest hierarchy. These data suggest that the identified genes are not dependent on the family of origin (i.e., APP SWE , APP ARC , or PSEN1 H163Y families) but they represent a group of genes that have similar expression between the wild type and the mutation carriers regardless of mutation.
Presymptomatic Diagnosis by Using a FAD Index. Distinct separation of the differential gene expression profile between the mutation carriers and the wild-type siblings was also obtained by PCA. As shown in Fig. 4 , PCA separates the mutation carriers from the wild types by a discrimination plane. The specific topological location and the distance to the discrimination plane are determined by the gene expression profile of the individual sample. To correctly locate a test sample in the space of the PC axes, a formula (the so-called FAD index) was obtained by calculating the coordinates of the three PC axes using Fisher's linear discriminant analysis. The FAD index indicates the level of similarity between a test sample and the mutation carriers, where positive values indicate similarity to mutation carriers (see Materials and Methods for details; more information is also available from the authors upon request). The mean FAD indexes obtained in the present study for mutation carriers and Fig. 2 . Relationship between CV value and the number of differentially expressed genes and prediction accuracy. Illustration of how the number of identified probe sets and the prediction accuracy depend on the chosen CV threshold. Allen's CV value for each gene was calculated for wild-type samples versus mutation carriers as shown in Materials and Methods. The left y axis shows the number of genes having a greater CV value than the threshold indicated at the x axis (E). LOOCV was performed with SVM to evaluate the accuracy of prediction of genotype classification of the removed sample using the genes obtained at each CV threshold. The prediction accuracy is indicated on the right y axis (■). CV threshold 3 corresponds to 200 genes, and threshold 4 corresponds to 56 genes. Fig. 3 . Unsupervised hierarchical cluster analysis of the signal intensity value of 30 samples. Unsupervised hierarchical clustering of the 30 samples was performed by using the signal intensity for the probe sets obtained for CV thresholds exceeding 3 (200 genes) and 4 (56 genes). After transformation to Z score, two-dimensional unsupervised hierarchical clustering was performed with the cosign correlation as a similarity measure. Relative distances of each probe set (vertical axis) and sample (horizontal axis) are also demonstrated. The wild-type samples (blue) cluster together at both CV thresholds, whereas the mutation carriers (pink) have a higher similarity at CV threshold 4. Red and green indicate higher and lower expression, respectively. 
Possible Influence of Other Factors on the Observed Gene Expression
Signature. Furthermore, we evaluated whether the identified genotype-dependent 200 probe sets were confounded by factors that previously have been associated with the onset of AD, such as age, gender, APOE 4 status, and phenotype (33) (34) (35) (36) . To evaluate this possibility, Allen's CV values were calculated for genotype, age, gender, APOE 4 status, and phenotype, followed by comparison of the CV values between the 200 probe sets and the remaining 10,938 probe sets. As shown in the Table 2 , the presence or absence of APOE 4, age, or gender did not significantly contribute to the observed differences in gene expression between mutation carriers and wild-type siblings.
Discussion
Microarrays may be used to study disease pathophysiology and classification. Previous AD-related gene expression studies have been focused on studying disease pathophysiology (8 -16) . In those studies, fold ratios and statistical significance testing have been used to determine differential gene expression among tissue samples, and the resulting information has been used to try to understand the disease process. Disease classification, however, uses class methods applied to expression profiles to compare diagnostic categories, discover disease subtypes, correlate phenotypical variables with gene expression patterns, and build models that predict clinical relevant variables, which might include diagnosis, prognosis, or management. This type of application has become an important aid in the molecular diagnosis and classification of human malignancies (21) (22) (23) (24) (25) (26) . It has also been shown that gene expression analysis can be used for predicting the clinical outcome of some cancers (37) (38) (39) (40) . In our study, we used class models to find a gene expression signature accompanying the early stages of FAD that may be further developed for presymptomatic diagnosis in the common forms of AD.
We performed a global mRNA expression profiling with DNA microarrays on RNA obtained from cultured fibroblasts prepared from individuals carrying one of three FAD mutations (APP SWE , APP ARC , or PSEN1 H163Y) and their nonmutationcarrying, wild-type siblings. Interestingly, our results indicate that the mutation carriers share a common gene expression signature significantly different from that of their wild-type siblings. Because both demented and healthy individuals were included among the mutation carriers, the present results lend support to the hypothesis that intrinsic properties for the disease process start several decades before the onset of cognitive decline. We do not attempt to discuss the possible pathogenic association of individual genes in the gene signature because the study was not designed to identify biochemical pathways in AD but rather to identify potential differences in gene expression levels for diagnostic classification.
It would be of great clinical value to be able to predict the onset of disease in presymptomatic individuals because it would be Fig. 4 . PCA of the signal intensity for the 200 genes from 30 individuals. The signal intensity of 200 genes for each individual sample was subjected to PCA, and each sample is represented on a coordinate composed of first, second, and fourth principal component axes. The vectors thus obtained were used to derive a formula for calculating a FAD index that reflects the similarity to a mutation carrier (see text for details). Pink, mutation carriers; blue, wild type. Allen's CV values were calculated for genotype-, age-, gender-, APOE 4 status-, and phenotype-dependent classifications for 11,138 probe sets (details available from the authors upon request). Then the average of the CV values for the 200 probe sets were derived from wild type͞mutation carrier analysis, and the remaining 10,938 were compared between class pairs. The average, standard deviation (shown in parentheses), and P values derived by Welch's t test are indicated.
possible to start early treatment and thus hopefully postpone the onset of cognitive symptoms. It is worth noting that we did investigate the possibility of finding a discriminating signature from peripheral blood lymphocytes. However, the interindividual variation and the RNA quality did not allow us to pursue the analysis, suggesting that lymphocytes are more sensitive to differences in external conditions during sampling as well as being very reactive to acute stimuli, such as nutritional status, fever, infections, and drug treatment, which makes them less attractive than fibroblasts. Although we find that fibroblasts are preferable to lymphocytes for the purpose of identifying gene signatures, it may be possible to find biological diagnostic markers from the 200 genes (available from the authors upon request), which could be used for tests on blood, cerebrospinal fluid, or, possibly, urine.
Although the number of differentially expressed genes might be able to be optimized in future, it still remains significant that there is a unique gene expression signature for FAD caused by three different mutations in two different genes and that it can be detected in fibroblasts, which may seem to be an organ completely unrelated to the tissue affected by the disease. It is likewise important that the gene expression signature is present before clinically detectable symptoms. The strategy to use gene expression signatures for diagnosis in easily obtainable but seemingly unrelated tissues to the disease may provide a novel approach for early diagnosis and patient treatment as well as pharmacogenomic studies.
